BioVex Revenue
Biotechnology Research • 
United Kingdom • 11-20 Employees
BioVex revenue & valuation
| Annual revenue | $10,000,000 |
| Revenue per employee | $500,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $32,000,000 |
| Total funding | $40,000,000 |
Key Contacts at BioVex
Jenifer Thomas
Senior Director Process Development
Paul Bullock
Director Of Cmc Development
Anna Idis
Owner
Company overview
| Headquarters | United Kingdom |
| Phone number | +441235441900 |
| Website | |
| Founded | 1999 |
| Employees | 11-20 |
| Socials |
BioVex Email Formats
BioVex uses 5 email formats. The most common is {first name}.{last name}@company.com (e.g., john.doe@company.com), used 42.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name}@company.com | john.doe@company.com | 42.1% |
{first name}@company.com | john@company.com | 25.3% |
{first name initial}{last name}@company.com | {first name initial}doe@company.com | 14.8% |
{first name}{last name}@company.com | johndoe@company.com | 10.2% |
{last name}@company.com | doe@company.com | 7.6% |
About BioVex
THOUSAND OAKS, Calif., March 4, 2011 /PRNewswire via COMTEX/ -- Amgen (Nasdaq: AMGN), today announced the completion of the acquisition of BioVex Group, Inc., a privately held biotechnology company based in Woburn, Mass., with additional operations in Abingdon, UK. The acquisition includes OncoVEX(GM-CSF), a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on Jan. 24. ABOUT BIOVEX -- BioVex is a privately held biotechnology company based in Woburn, Mass. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease. The Company’s lead product, OncoVEXGM-CSF is a first in class oncolytic vaccine. OncoVEXGM-CSF is currently being evaluated in a Phase 3 multi-national study in metastatic melanoma and a Phase 3 study in head and neck cancer is scheduled to commence in the second half of 2010. BioVex believes OncoVEXGM-CSF has the potential to become a leading standard of care in the treatment of many solid tumors based on the strength of clinical data so far generated coupled with the relatively benign side effect profile noted to date. The Company has recently also commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes.
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
BioVex has 5 employees across 3 departments.
Departments
Number of employees
Croatia
Frequently asked questions
4.8
40,000 users
